150
Participants
Start Date
February 5, 2021
Primary Completion Date
July 26, 2022
Study Completion Date
July 26, 2022
3mg AZ-010
Subjects who received a single inhaled dose (3mg)
1mg AZ010
Subjects who received a single inhaled dose (1mg)
Staccato Placebo
Subject who received a single inhaled dose (Staccato Placebo)
NY Scientific, Brooklyn
University of Pittsburgh Medical Center, Pittsburgh
Temple University Hospital, Philadelphia
Infinite Clinical Trials, Morrow
Summit Clinical Studies, Athens
University of South Florida, Tampa
New Phase Research & Development, LLC, Knoxville
Henry Ford Health System, Detroit
Medical College of Wisconsin, Milwaukee
Mayo Clinic, Rochester
Kansas University Medical Center, Kansas City
Baylor College of Medicine, Houston
Pioneer Research Solutions, Houston
Sante Clinical Research, Kerrville
Axis Clinical Trials, Los Angeles
Precision Research Institute, LLC, San Diego
Om Research, Lancaster
Massachusetts General Hospital, Boston
Lead Sponsor
Alexza Pharmaceuticals, Inc.
INDUSTRY